医护一体化模式联合营养饮食指导对食管癌围手术期患者QLQ-C30评分的影响

目的分析医护一体化模式食管癌手术患者应用医护一体化模式联合营养饮食指导的效果。方法选取2020年1月至2022年10月期间在河南省胸科医院收治的90例食管癌手术患者,随机分为对照组(n=44)和观察组(n=46)。观察组予以医护一体化护理联合营养饮食指导,对照组予以常规护理。比较两组患者术后恢复情况、应激反应水平、心理状态、生活质量以及术后并发症发生率。结果两组引流量比较,差异无统计学意义(P>0.05);两组排气时间、拔管时间、住院时间相比,观察组短于对照组,差异有统计学意义(P<0.05)。护理后,两组患者应激反应均降低,观察组低于对照组,差异有统计学意义(P<0.05)。护理后,两组患者心理状态均有所改善,观察组优于对照组,差异有统计学意义(P<0.05)。护理后,两组患者生活质量水平均有所提高,观察组高于对照组,差异有统计学意义(P<0.05)。两组患者并发症发生率相比,观察组较低,差异有统计学意义(P<0.05)。结论医护一体化模式联合营养饮食指导应用于食管癌围手术期患者,可降低患者应激反应,缓解患者负性情绪,提高生活质量,降低术后并发症发生,加快患者恢复进程。

Quality of life after laparoscopic vs open sphincter-preserving resection for rectal cancer

AIM: To compare quality of life (QoL) outcomes in Chinese patients after curative laparoscopic vs open surgery for rectal cancer. METHODS: Eligible Chinese patients with rectal cancer undergoing curative laparoscopic or open sphincterpreserving resection between July 2006 and July 2008 were enrolled in this prospective study. The QoL outcomes were assessed longitudinally using the validated Chinese versions of the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQCR38 questionnaires before surgery and at 4, 8, and 12 mo after surgery. The QoL scores at the different time points were compared between the laparoscopic and open groups. A higher score on a functional scale indicated better functioning, whereas a higher score on a symptom scale indicated a higher degree of symptoms.RESULTS: Seventy-four patients (49 laparoscopic and 25 open) were enrolled. The two groups of patients were comparable in terms of sociodemographic data, types of surgery, tumor staging, and baseline mean QoL scores. There was no significant decrease from baseline in global QoL for the laparoscopic group at different time points, whereas the global QoL was worse compared to baseline beginning at 4 mo but returned to baseline by 12 mo for the open group (P = 0.019, Friedman test). Compared to the open group, the laparoscopic group had significantly better physical (89.9±1.4 vs 79.2±3.7, P = 0.016), role (85.0±3.4 vs 63.3±6.9, P = 0.005), and cognitive (73.5±3.4 vs 50.7±6.2, P = 0.002) functioning at 8 mo, fewer micturition problems at 4-8 mo (4 mo: 32.3±4.7 vs 54.7±7.1, P = 0.011; 8 mo: 22.8±4.0 vs 40.7±6.9, P = 0.020), and fewer male sexual problems from 8 mo onward (20.0±8.5 vs 76.7±14.5, P = 0.013). At 12 mo after surgery, no significant differences were observed in any functional or symptom scale between the two groups, with the exception of male sexual problems, which remained worse in the open group (29.2±11.3 vs 80.0±9.7, P = 0.026). CONCLUSION: Laparoscopic sphincter-preserving resection for rectal cancer is associated with better preservation of QoL and fewer male sexual problems when compared with open surgery in Chinese patients. These findings, however, should be interpreted with caution because of the small sample size of the study.

Value of quality of life analysis in liver cancer: A clinician's perspective

Health related quality of life(HRQOL) is increasingly recognized as an important clinical parameter and research endpoint in patients with hepatocellular carcinoma(HCC). HRQOL in HCC patients is multifaceted and affected by medical factor which encompasses HCC and its complications, oncological and palliative treatment for HCC, underlying liver disease, as well as the psychological, social or spiritual reaction to the disease. Many patients presented late with advanced disease and limited survival, plagued with multiple symptoms, rendering QOL a very important aspect in their general well being. Various instruments have been developed and validated to measure and report HRQOL in HCC patients, these included general HRQOL instruments, e.g., Short form(SF)-36, SF-12, Euro Qo L-5D, World Health Organization Quality of Life Assessment 100(WHOQOL-100), World Health Organization Quality of Life Assessment abbreviated version; general cancer HRQOL instruments, e.g., the European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30, Functional Assessment of Cancer Therapy(FACT)-General, Spitzer Quality of Life Index; and liver-cancer specific HRQOL instruments, e.g., EORTC QLQ-HCC18, FACT-Hepatobiliary(FACT-Hep), FACT-Hep Symptom Index, Trial Outcome Index. Important utilization of HRQOL in HCC patients included description of symptomatology and HRQOL of patients, treatment endpoint in clinical trial, prognostication of survival, benchmarking of palliative care service and health care valuation. In this review, difficulties regarding the use of HRQOL data in research and clinical practice, including choosing a suitable instrument, problems of missing data, data interpretation, analysis and presentation are examined. Potential solutions are also discussed.

Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy:quality of life in high-risk prostate cancer patients

Aim： To present preliminary results on health-related quality of life （QoL）, prostate-associated symptoms and therapeutic effects of targeted-cryosurgical ablation of the prostate （TCSAP） with androgen deprivation therapy （ADT） in high-risk prostate cancer （PCa） patients. Methods： Thirty-four men with high-risk PCa features underwent TCSAP, and ADT was added to improve the treatment outcomes. High-risk parameters were defined as either prostate-specific antigen （PSA） ≥ 10ng/mL, or Gleason score 〉 8, or both. The Genito-Urinary Group of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 （EORTC QLQ-C30） with prostate-cancer-specific module （QLQ-PR25） was used for evaluating morbidities and PSA levels were recorded every 3 months. PSA failure was defined as the inability to reach a nadir of 0.4 ng/mL or less. Results： Although it was not statistically significant, the global health status scores increased after TCSAP with ADT. The scores for five functional scales also became higher after treatment. The most prominent symptom after treatment was sexual dysfunction, followed by treatment-related and irritative voiding symptoms. Conclusion： TCSAP with ADT appears to be minimally invasive with high QoL except for sexual dysfunction. Long-term follow-up of PSA data and survival is necessary before any conclusions can be made on the efficacy of this promising new therapeutic modality in the treatment of PCa.

Quality of Life in Women with Endometriosis Pelvic Pain Treated with the Levonorgestrel-Releasing Intrauterine System

Objective: To evaluate the quality of life in patients with endometriosis pelvic pain before and after the application of the levonorgestrel-releasing intrauterine system (LNG-IUS). Design: Open non-comparative study. Setting: Obstetrics and Gynecology Hospital at Monterrey, Mexico. Sample: 29 women aged 18 to 40 years with pelvic pain associated with endometriosis confirmed by laparoscopy. Methods: After laparoscopy but before LNG-IUS insertion (basal visit) and 6 months afterwards, modified Endometriosis Health Profile (EHP-30) was applied. Main outcomes measures: Size of change of questionnaire scores, need of additional analgesic therapy and adverse effects. Statistical Analysis: Differences in the questionnaire scores before and after intervention were analyzed by Student t-test. Results: Final analysis set included 29 women aged 31.7 ± 4.7 years years. The ASRM surgical staging of endometriosis was mild in 19.3 moderate in 13.7 and severe in 76% of the patients. The general perception of quality of life improved from 52 at baseline to 98% at six months (p < 0.001). Adverse events were mild in nature, 19 patients reported no adverse events during the study (65.5%). Two patients (6.9%) required the use of concomitant therapy with non-steroidal analgesics for relief of pain. Conclusion: The application of LNG-IUS in patients with pelvic pain associated with endometriosis improved significatively all aspects related with quality of life as measured with Endometriosis Health Profile (EHP-30). We concluded that LNGIUS may be an effective and convenient therapeutic alternative for the management of pain associated with endometriosis.

Pre- and Post-Surgical Health-Related Quality of Life Evaluation of Esophageal Carcinoma Patients

For patients with esophageal carcinoma (ESCA), health-related quality of life (HRQoL) has now become an essential feature. To examine the quality of life of preoperative and postoperative ESCA patients, we used the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C-30) and the Quality of Life Questionnaire Oesophageal 18 (QLQ-OES18). Using the EORTC QLQ-C30 and the QLQ-OES18 questionnaire, the analysis of the quality of life scores of 246 patients with oesophageal cancer who were operated on at the Sun Yat-sen University Cancer Centre during the period 2013 to 2015 was carried out. Differences between pre- and post-surgical EORTC QLQ C-30 and QLQ-OES18 scores were examined using the Student’s t-test. Patients’ global health status (QoL) decreased significantly one month after the operation but gradually recovered within a year. In terms of the role function, the emotional function, the cognitive function, and the perception and function variants, EORTC QLQ-C30 and QLQ-OES18 scores increased statistically significantly, as did clinical signs variables such as exhaustion, nausea, vomiting, pain, sleeplessness, decreased appetite, stomach pain, and economic hardship. After surgery, there was an improvement in functional and symptom domains in esophageal carcinoma patients. EORTC QLQ-C30 and QLQ-OES18 can be used to assess the HRQoL before and after surgical procedures.

Quality of Life in Ovarian-Cancer Patients Receiving Chemotherapy

Background: Ovarian cancer accounts for 4% of cancers occurring in women and ranks first in gynecological cancer mortality. Maintaining and improving quality of life is an important goal of cancer treatment. The toxicities of cancer treatment particularly chemotherapy can impact an individual’s wellbeing. Objective: Assessment of quality of life among ovarian cancer patients receiving chemotherapy. Method: A descriptive study was conducted among 202 patients with ovarian cancer treated at the National Institute of Cancer Research and Hospital in Bangladesh. Ethical approval was received from the ethics committee of NICRH. Data was collected using the EORTC QLQC30 questionnaire and the ovarian cancer specific EORTC QOL OV-28 module. Functional, symptomatic and global variables were scored and analyzed by SPSS. Multiple linear regressions determined the effects of predictor variables and correlation of the global health status with other variables. Results: 48.6% of patients were ages 41 to 50 years. The mean score of global health status was 55.77. Deteriorating emotional function, distressing physical and psychological symptoms, sexual dysfunction and financial difficulties adversely affect the quality of life. Their correlation with global health status was strongly significant (P value < 0.05). Fatigue (r value -0.604;p < 0.05) loss of appetite (r value -0.442;p < 0.05), insomnia (r value -0.339;p < 0.05), dyspnea (r value -0.377;p < 0.05), heartburn (r value -0.369;p < 0.05), and alopecia (r value -0.262;p < 0.05) were negatively associated with QOL. Conclusion: The overall quality of life among the ovarian cancer patients receiving chemotherapy is low. Increasing knowledge in this area will help clinicians to optimize patient management. Interventions should focus on both physical and psychological and sexual health issues that adversely affect the quality of life.

门冬胰岛素30联合二甲双胍调节2型糖尿病病人血糖指标和生活质量的体会

目的探讨门冬胰岛素30联合二甲双胍调节2型糖尿病病人血糖指标和生活质量的体会。方法选取本院2020年1月-2022年8月收治的56例2型糖尿病患者纳入研究,将所有患者随机打乱并分为常规组以及研究组,每组28例。常规组采取单独的门冬胰岛素30进行治疗,研究组则通过门冬胰岛素30与二甲双胍进行联合治疗。比较两组患者的临床疗效、空腹血糖、餐后2h血糖、睡眠质量、生活质量以及血脂相关指标。结果研究组临床有效率较之于常规组更高,组间比较存在统计学意义(P<0.05);研究组治疗后的餐后2h血糖以及空腹血糖较之于常规组更低,组间比较存在统计学意义(P<0.05);治疗前两组患者的睡眠质量与生活质量差异不显著(P>0.05),治疗后研究组两项指标均显著优于常规组,组间比较存在统计学意义(P<0.05);研究组患者的HDL-C、LDL-C、TC以及TG指标较之于常规组更低,组间比较存在统计学意义(P<0.05)。结论将二甲双胍以及门冬胰岛素30联合应用于2型糖尿病患者的治疗中,可以有效控制并降低患者血脂、血糖相关指标,同时促进患者睡眠质量和生活质量得到进一步提高,治疗效果显著,具有极高的临床应用价值,值得推广使用。

QLQ-30量表在乳腺癌化疗患者中的应用

应用EORTC QLQ-30核心量表调查初治乳腺癌化疗患者的生存质量。运用自身对比的队列研究方式,调查了42名乳腺癌化疗患者。结果显示化疗带来的生存质量的下降是显著但短暂的;某些因素对生存质量的影响较大,值得针对性地采取干预措施;对一些调查项目的修改,可以使EORTC QLQ-30量表更好地适应我国的国情和文化。

门冬胰岛素30联合二甲双胍治疗T2DM的临床疗效及对患者血糖及血脂水平影响的研究

目的探讨和分析门冬胰岛素30联合二甲双胍治疗T2DM的临床疗效及对患者血糖和血脂水平的影响。方法选取2015年1月至2017年12月期间于我院接受治疗的104例T2DM患者作为此次研究对象,在患者知情并自愿参与的原则下,双盲法随机分为对照组(52例)和研究组(52例)。其中对照组给予二甲双胍治疗,研究组在此基础上再联合门冬胰岛素30治疗,持续治疗12w后,对两组患者血糖、血脂水平及生存质量(QOL-BRE)进行对比分析。结果治疗后,两组患者FPG、2h PG和Hb A1c水平较治疗前均呈显著性下降(P<0.05),且研究组下降水平与对照组相比,差异具有统计学意义(P<0.05);与治疗前相比,治疗后两组患者的TC、TG和LDL-C下降,HDL-C上升,差异具有统计学意义(P<0.05),且治疗后研究组血脂水平较对照组,差异同样具有统计学意义(P<0.05);两组患者治疗后的QOL-BREF评分均显著高于治疗前(P<0.05),且研究组QOL-BREF评分较对照组,差异具有显著性差异(P<0.05)。结论门冬胰岛素30联合二甲双胍治疗T2DM能显著控制血糖、血脂水平,并提升患者生存质量,是一种值得推荐的临床联合用药方案。

External validation of the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer colorectal(CR29)module:Monocentric study

BACKGROUND Quality of life(QoL)outcomes are a focal endpoint of cancer treatment strategies.AIM To externally validate the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer(EORTC)QoL Questionnaire(QLQ)for colorectal cancer(CRC)patients(CR29).METHODS Both Moroccan Arabic modules of QLQ-CR29 and QLQ-C30 were administered to Moroccan CRC.Psychometric properties were retested by measuring Cronbach’s alpha coefficient for reliability and Intraclass correlation coefficient(ICC)to examine test-retest reproducibility.The multitrait-scaling analysis was performed to demonstrate the validity of the instrument and known-groups comparison was used to test the score’s ability to discriminate between different groups of patients.RESULTS In total,221 patients were included in our study and 34 patients completed the questionnaire twice.The Urinary Frequency scale and Stool Frequency scale had good internal consistency with alpha Cronbach coefficients of 0.79 and 0.83 respectively,while the same coefficients were moderately lower for the Blood and Mucus in Stool scale(0.61)and the Body Image scale(0.67).The ICCs ranged from 0.88 to 1 indicating good to excellent reproducibility.In multitrait scaling analyses,the criterion for item convergent and divergent validity was satisfactory.The known-group comparison showed statistically significant differences between patients according to age,gender,stoma status,tumor location,and radiotherapy.CONCLUSION The Moroccan Arabic version of the EORTC QLQ-CR29 is a valid and reliable tool that can be used safely for research and clinical purposes in Moroccan CRC patients.

中医治疗子宫内膜异位症研究中生活质量量表的应用评价

【目的】对中医治疗子宫内膜异位症研究文献中生活质量量表的使用情况进行评价。【方法】检索中文数据库如中国生物医学文献数据库(CMB)、中国知网(CNKI)、维普期刊数据库(VIP)和万方数字化期刊数据库(Wanfang Data)以及英文数据库如PubMed、Embase和CINAHL中有关中医治疗子宫内膜异位症的临床研究文献,对符合要求的文献中的量表应用情况进行分析。量表应用评价从量表选择(是否规范使用量表)、量表使用分析(包括量表维度报告与量表维度分析)、研究设计(是否考虑了混杂因素)和量表参照版本4个方面进行。【结果】共纳入有关中医治疗子宫内膜异位症研究的文献103篇,其中35篇文献选用了专科性量表的子宫内膜异位症生存质量量表EHP-5或EHP-30(合称为EHP-5/30);19篇文献选用了普适性量表的生活质量简表SF-12或SF-36(合称为SF-12/36),另有19篇文献选用了普适性量表的世界卫生组织生存质量测定量表(WHOQOL);12篇文献只说明选用了生存质量量表;10篇文献选用了其他普适性量表;3篇文献选用了妇科专科量表;3篇文献同时选用了2种生存质量量表;2篇文献选用了自制的生存质量量表。纳入分析的文献共涉及9种量表,48篇文献选用了普适性量表,38篇文献选用了专科性量表;使用频率较高的量表为EHP-5/30(35/105,33.98%)、SF-12/36和WHOQOL(均为19/105,18.45%),而其使用规范率则为WHOQOL>SF-12/36>EHP-5/30。涉及的9种量表中,只有2种为国内原创量表,可见于5篇文献中,其余皆为从国外引入的量表。【结论】中医治疗子宫内膜异位症的临床研究中,生活质量量表的选择以国外量表为主,专科性和普适性量表平分秋色,存在量表使用规范情况欠佳、研究者对其重视不足、评价方法不合理等问题。今后的研究需重视生活质量量表的使用及分析的规范性和准确性,以期提升中医药临床研究成果的可信度。

癌症生存者生活质量及影响因素的调查分析

探讨不同癌症生存者的生活质量状况及其影响因素,对癌症部位、患病时间不同的癌症生存者148名,采用生活质量问卷(EORTCQLQ-30)进行测量。结果:不同年龄组之间RF、EF、SL和FI得分有统计学差异;男女患者在SF、AP和QOL方面有统计学差异。不同文化程度患者之间PF、RF、FA、NV和AP有统计学差异。患病时间与总体生活质量(QOL)之间相关性有统计学意义。不同种类癌症患者之间SF、DY、AP得分有统计学差异。有无复发或转移、是否接受手术治疗以及目前是否正在进行化疗均会对癌症生存者的生活质量产生影响。结论:人口学特征及疾病等因素均会不同程度的影响到癌症生存者的生活质量,提示医务人员应根据癌症生存者不同的特点进行有的放矢的治疗和护理,在延长其生存时间的同时也应注意提高其生活质量。

卵巢癌患者生活质量的相关影响因素研究

目的:研究影响卵巢癌患者生活质量的相关因素。方法:对66例卵巢癌患者采用生活质量问卷(EORTCQLQ-30)进行调查。对收入、年龄、病情、医疗费用来源进行相关性分析。结果:卵巢癌患者生活质量较差;患者的生活质量随收入的增加而提高,随疾病的严重程度而降低,随着年龄的增大而提高。结论:收入、年龄、病情、医疗费用来源与卵巢癌患者的生活质量相关。

放射性粒子植入治疗肺癌患者的生活质量调查及护理干预

目的探讨放射性粒子植入治疗肺癌患者的生活质量及护理干预。方法选取70例采用放射性粒子植入治疗肺癌患者为研究对象,于治疗前及治疗后12周采用生活质量量表(EORTCQLQ-30)调查。结果患者治疗12周后总有效率为40.0%。患者治疗12周后EORTCQLQ-30评分中的失眠、食欲减退、困乏、疼痛、呼吸困难以及社会功能、情绪评分均低于治疗前(P<0.05)。结论放射性粒子植入治疗能够缩小肺癌患者的病灶,缓解临床症状,但治疗后患者易出现疼痛、呼吸困难、失眠、困乏等症状,生活质量降低,应重视不良反应的护理干预,确保疗效,提高患者生活质量。

非洛地平缓释片治疗肾性高血压的临床疗效及对生活质量的改善作用

目的探讨钙离子拮抗剂非洛地平缓释片治疗肾性高血压的临床疗效及对生活质量的影响。方法将100例肾性高血压患者随机分为2组,每组50例。对照组给予福辛普利钠片,观察组给予非洛地平缓释片。比较2组患者总体疗效,血压、尿蛋白、血肌酐、生活质量的改善以及不良反应发生率。结果观察组总有效率显著高于对照组;2组患者治疗后血压、尿蛋白及血肌酐水平均较治疗前显著改善,而观察组尿蛋白水平的改善幅度显著大于对照组;观察组生活质量核心问卷-30(QLQC-30)各项评分均显著高于对照组。观察组不良反应发生率有低于对照组的趋势,但差异无统计学意义。结论钙离子拮抗剂非洛地平缓释片治疗肾性高血压疗效显著,可明显提高患者治疗后生活质量,应在临床上加以推广应用。

中医食疗对调理高血压患者痰湿体质、控制血压、提高生存质量和降低血脂作用的分析

目的:探讨中医食疗对调理高血压患者痰湿体质、控制血压、提高生存质量和降低血脂的作用。方法:将100例高血压患者(痰湿体质)随机分为2组,对照组给予常规健康宣教,观察组在此基础上给予中医食疗。比较2组干预前后不同时间点痰湿体质分值的变化情况、干预前后血压、血脂变化以及干预后患者生存质量。结果:①对照组干预4、8、12周与干预前比较,差异均无统计学意义(P>0.05),观察组各时间点与对照组比较,差异具有统计学意义(P<0.05);②收缩压及舒张压对照组干预前后比较,差异均无统计学意义(P>0.05),观察组干预前后比较,差异均具有统计学意义(P<0.05),2组干预后相比,差异具有统计学意义(P<0.05);③总胆固醇(TC)、甘油三酯(TG)对照组干预前后比较,差异均无统计学意义(P>0.05),观察组干预前后比较,差异均具有统计学意义(P<0.05),且2组干预后相比,差异具有统计学意义(P<0.05);④对照组生活质量问卷(QLQC-30)各项指标评分均要明显低于观察组(P<0.05)。结论:中医食疗对调理高血压患者痰湿体质、控制血压、提高生存质量和降低血脂均具有一定的促进意义。

替扎尼定联合文拉法辛缓释片治疗紧张性头痛的疗效分析

目的探讨替扎尼定联合文拉法辛缓释片治疗紧张性头痛的临床疗效。方法选取在我院神经科住院治疗的98例临床确诊的紧张性头痛患者,随机分为治疗组和对照组,每组49例,治疗组采用替扎尼定联合文拉法辛缓释片治疗,对照组采用替扎尼定治疗,两组均于治疗前、治疗后第2周、第4周分别采用视觉模拟评分法(VAS)记录疼痛分值,且于治疗结束前及治疗后用生活质量核心量表(QLQ-C30)对患者生活质量改善情况进行评定。结果治疗前治疗组及对照组VAS、QLQ-C30评分比较差异无统计学意义(P>0.05)。治疗后第2周、第4周VAS评分与治疗前相比,结果示治疗组、对照组VAS评分差异均有统计学意义(P<0.05),但治疗组VAS评分改善明显优于对照组,差异有统计学意义(P<0.05)。治疗后第4周治疗组、对照组QLQ-C30评分与治疗前比较,差异有统计学意义(P<0.05),但治疗组QLQ-C30评分改善优于对照组,差异有统计学意义(P<0.05)。结论替扎尼定联合文拉法辛缓释片治疗紧张性头痛安全、可靠,值得临床推荐。

贲门癌根治性全胃切除术与根治性近端胃切除术的临床效果对比

〔目的〕探讨贲门癌根治性全胃切除术与根治性近端胃切除术的临床效果。〔方法〕病例来源于我院2009年5月至2012年5月收治确诊的贲门癌患者142例。依据随机数字表法将这些患者均分为观察组和对照组,每组各71例。给予观察组根治性全胃切除切除手术,给予对照组则进行根治性近端胃切除术,观察比较两组患者的QLQC-30、并发症等指标。〔结果〕观察组手术时间、术中出血量、术后3 d胃管引流量、术后排气时间及术后3 d白蛋白值与对照组比较差异不明显,不存在统计学意义(P>0.05);观察组术后吻合口狭窄、反流性食管炎以及总的并发症发生情况与对照组比较差异明显,存在统计学意义(P<0.01);观察组术后短期内生活质量评分中QLQC-30问卷的各个项目以及术后1a、3 a生存率均明显优于对照组,比较差异存在统计学意义(P<0.01)。〔结论〕根治性全胃切除术与根治性近端胃切除术相比,临床疗效较好,安全有效,具有重要的临床应用价值。

Impaired of Sexuality in Premenopausal Breast Cancer Patients

Introduction: The treatment modalities for Breast cancer may impair the sexual function of women, especially in the pre-menopausal period. Treatment in this group of women has a huge impact in quality of life. The main objective of this study was to evaluate the prevalence of sexual dysfunction (SD) after treatment for breast cancer among women who were premenopausal at the diagnosis of neoplasia. Material and Methods: All women diagnosed with premenopausal breast cancer at one outpatient clinic from March 2019 to September 2020 were selected. Participants answered two sexual function questionnaires (the Female Sexual Function Index [FSFI-19] and Female Sexual Quotient [QS-F]) and a quality of life [QOL] questionnaire [EORTC QLQ-C30]). Sociodemographic and tumor characteristics were also studied. Results: Fifty-eight pre-menopausal women were included. Sexual dysfunction (SD) was observed in 43 participants (74.1%) according to the FSFI-19, while 31 (53.4%) had SD according to the QS-F. The functional and general health scales of the EORTC QLQ-C30 were positively related to the FSFI-19 and QS-F scores, while the symptom scale was negatively related to the FSFI-19 and QS-F scores. There was no relationship between chemotherapy, hormone therapy, or surgery with the FSFI-19 and QSF scores. A diagnosis of depression was negatively related to the total FSFI-19 scores. Conclusion: Pre-menopausal breast cancer women showed high rates of female SD. None breast cancer treatment modality was related to SD. The only studied variable associated with SD was depression.